News

Hoth Therapeutics and Washington University have agreed to extend preclinical research into HT-ALZ, Hoth’s experimental therapy for Alzheimer’s disease. Research findings are expected to be helpful in estimating the best dose of HT-ALZ to test in potential clinical trials, according to a company press release. Hoth entered into…

Caring for a loved one with Alzheimer’s disease (AD) can be overwhelming. To help ease the caregiver burden — and ultimately benefit patients — a Florida-based company called VirtuALZ is offering a new virtual support program. Crafted specifically to support caregivers of patients who have Alzheimer’s and related…

UsAgainstAlzheimer’s is preparing to launch free online courses — The Brain Health Academy — teaching health and wellness professionals how to help people reduce the risk of Alzheimer’s and dementia. Developed in partnership with the American Heart Association, The American College of Lifestyle Medicine, and the Centers for…

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will…

An innovative new project in Toronto will combine optometry and community-based cognitive testing to improve Alzheimer’s screening and enable the early detection of the progressive neurodegenerative disorder. The project — launching in Ontario, Canada — will be led by the medical imaging company RetiSpec and the community-based medical center…

The start of summer holds the promise of beach trips, barbecues, and vacations, but for people with Alzheimer’s disease and their caregivers, family, and friends, June also means Alzheimer’s and Brain Awareness Month. Monthlong initiatives aim to honor the more than 55 million people living with dementia worldwide, according…

C2N Diagnostics has developed a new assay that precisely measures blood levels of four forms of tau, a protein involved in the brain changes observed in Alzheimer’s disease. Called the plasma tau multianalyte assay (p-tau MAA), the test is intended to be used for research purposes only and…

When Lewis Hornby’s grandmother was rushed to the hospital in 2018, his family feared the worst. Pat Dickinson suffered from dementia, but in this instance it turned out that she was simply dehydrated. Once she got some fluids in her, she bounced back. But what happened to his grandmother gave…

The Einstein Aging Study has received a $32 million grant from the National Institutes of Health (NIH) to delve into the many risk factors that may determine cognitive decline and disease progression in people with Alzheimer’s. The study, ongoing at the Albert Einstein College of Medicine since…

Alzamend Neuro has dosed the first patient in the multiple ascending dose portion of its Phase 2a clinical trial of AL001, an investigational oral therapy for dementia related to Alzheimer’s disease. This multiple ascending dose (MAD) part follows positive results from a Phase 1 trial. Topline data…